A miscellaneous group of drugs, whose ability to inhibit angiogenesis involves mechanisms that are either nonspecific or are not clearly understood, is also being tested in cancer patients. One example, a drug called CAI, exerts its effects by inhibiting the influx of calcium ions into cells. While this inhibition of calcium uptake suppresses the growth of endothelial cells, such a general mechanism may affect many other cellular processes.